OncoBone Ventures presented exciting data of its OBP-001 asset in ENA 2022 Symposium

OncoBone Ventures attended 34th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain on October 26 – 28. In the Symposium Tiina Kähkönen, CSO of OncoBone Ventures presented a poster titled “Neutralizing Antibody for S100A8/A9 Soil Sensing Signal to Prevent Metastatic Disease” (you can watch the presentation from the following link: ENA presentation).

The poster was prepared in collaboration with Okayama University. It shows a summary of the preclinical work demonstrating a role for S100A8/A9 and its receptors in metastasis of melanoma, breast and lung cancer, and development of OBP-001, a neutralizing monoclonal antibody targeting S100A8/A9 that prevents formation of lung metastases in melanoma and breast cancer animal models.

Tiina Kähkönen, CSO of OncoBone Ventures says: “Based on current scientific evidence S100A8/A9 is a potential osteoimmuno-oncology (OIO) target for patients with bone metastases. We will continue by evaluating efficacy of OBP-001 in breast cancer bone metastasis models and are excited to share the progress in future scientific events.”